AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01657370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-1602
Description: Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration.
Study NCT01657370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three administrations of placebo for MK-1602 on separate days. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).~Dosage form is film coated tablet for oral administration.
Study NCT01657370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rescue medication
Description: If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans, opiates or other medication not explicitly excluded.
Study NCT01127373 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Multi-Beam Intensity-Modulated Radiation Therapy
Description: IMRT with multiple beams will be utilized to treat the breast or chest wall and axillary, supraclavicular and internal mammary lymph nodes. Treatment will be delivered once a day, 5 days a week for approximately 5 weeks. All missed radiation treatment visits will be made up. Daily set-up error will be checked prior to the delivery of every treatment.
Study NCT01127373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BreastQ questionnaire-
Description: MSKCC Department of Surgery. For patients who received a mastectomy with or without reconstruction, the questionnaire will be administered at baseline and 5-7 months after treatment.
Study NCT02214550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclic microgestin 1/20
Description: Cyclic OC Use - Participants will ingest pills containing active hormones for 21 days followed by 7 days of no pills, and then the cycle will repeat
Study NCT02214550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: continuous microgestin 1/20
Description: Continuous OC use - Pills containing hormones will be taken every day for 1 year
Study NCT01382199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactoferrin
Study NCT02655458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elotuzumab
Description: The following must also be administered before any elotuzumab:~Dexamethasone 8 mg IV (on the day of elotuzumab infusion 45-90 mins prior to the start of infusion), the following 30 - 90 minutes prior to start of infusion: H1 blocker: diphenhydramine (25 - 50 mg po or IV) or equivalent, H2 blocker: ranitidine (50 mg IV) or equivalent (adjusted for renal failure as indicated), acetaminophen (650 - 1000 mg po).
Study NCT02602171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oldenburger sentence test, localization test
Study NCT03277768 — intervention group
Intervention type: DEVICE
Intervention: Resonance Raman Spectroscopy (RRS)
Description: Pre and post-ductal RRS measurements will be obtained daily for a maximum of 14 data collection times in infants with and without PDAs.
Study NCT04752124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Therapy
Description: High intensity speed based interval treadmill training
Study NCT04752124 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: conventional therapy
Description: conventional physical therapy
Study NCT04752124 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional therapy
Description: conventional physical therapy
Study NCT05336006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity aerobic training with high protein diet
Description: High-intensity aerobic training (HAT) was given at 50 to 70 percent of maximum heart rate. Subsequent to stretching, the subjects were asked to do 30 mins of HAT exercises; consisting of 20 mins on the treadmill and 10 mins on a cycle ergometer at 50 to 70 % of MHR, lastly, 10 mins of cool down was performed.~Next the participants, in this group A were prescribed with strength training exercises with resistance depending upon each subject's individual muscle assessment.~In addition to these physical training exercises, this group also received a high protein diet in the range of 1.1 - 1.3 g/kg protein/ ideal body weight/day (>1 g/kg aBW/d), as prescribed by a qualified nutritionist.
Study NCT05336006 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: This group is considered a control group and they were allowed to follow their regular physical activities and dietary pattern.
Study NCT02812446 — intervention group
Intervention type: OTHER
Intervention: IAI infection
Study NCT02812446 — intervention group
Intervention type: OTHER
Intervention: Staphylococcus aureus nasal carriage infection
Study NCT01948895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desvenlafaxine
Description: Patients will be initiated on 50 mg/day of Desvenlafaxine. No dose changes will be allowed for the first four weeks. If there is partial or no response after four weeks, dosage will then be increased to 100mg/day, based on tolerability and the Investigator's judgment.
Study NCT01797991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone per os
Study NCT01797991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo for dexamethasone IV
Study NCT01797991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone IV
Study NCT01797991 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo for dexamethasone per os
Study NCT03177265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text messaging prior to first counseling call
Description: This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive up to 8 text messages prior to the first counseling phone call to provide education regarding cessation treatment.
Study NCT03177265 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text-to-Enhance
Description: Two weeks following receipt of the letter (PrO condition) or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
Study NCT03177265 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mail Notice
Description: This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive a notice in the mail that they will receive a phone call in about 2 weeks to offer telephone cessation treatment.
Study NCT03177265 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telephone Counseling
Description: Two weeks following receipt of the mailed notice or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
Study NCT04227392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: vaginal radiofrequency
Description: 2 sessions of vaginal radiofrequency therapy with 3 week interval. A session last 20 minutes.
Study NCT04768699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQG203
Description: TQG203,30µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
Study NCT04768699 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQG203/NovoSeven®
Description: In each of the two study periods (separated by a washout about two days),a single dose of TQG203 or NovoSeven® will be administered.TQG203 or NovoSeven®,90µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1.
Study NCT04768699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQG203/NovoSeven®
Description: In each of the two study periods (separated by a washout about two days),a single dose of TQG203 or NovoSeven® will be administered.TQG203 or NovoSeven®,90µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1.
Study NCT04768699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQG203
Description: TQG203,180µg/kg body weight, will be administered as intravenous (i.v.) administration over a period about 2minutes (min) on Study Day 1 once.
Study NCT01811901 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Reduction of DTN
Description: 15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
Study NCT01216449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous Citalopram
Description: Single dose of 20mg parenteral citalopram diluted in 250mL of 0.9% sodium chloride solution, infused over 30 minutes
Study NCT01216449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Single dose of 250mL of 0.9% sodium chloride solution, infused over 30 minutes
Study NCT02655458 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: On the days of elotuzumab administration, the dose of lenalidomide is to be administered at least 2 hours after completion of elotuzumab dosing. Aspirin 81 mg PO daily will also be prescribed for DVT prophylaxis.
Study NCT02655458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous PBMC reconstitution
Description: Autologous peripheral blood mononuclear cell collection and reconstitution. PBMC will be collected from patients by standard apheresis procedures. Up to 25 ml of autologous plasma will also be recovered for dilution of cryopreserved products (if necessary). For reconstitution, Patients will be pre-medicated as per each institution's standard protocols prior to reinfusion of PBMC products. Patient ID will be checked and verified by nursing staff and the products will be re-infused by continuous intravenous infusion pump. Patient vital signs will be monitored every 15 minutes for the duration of the procedure as per standard reinfusion protocol.
Study NCT02655458 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ASCT
Description: Autologous peripheral blood stem cell transplantation. (stem cells from the patient's own marrow are harvested, stored and then returned to the body (engrafted). To be done as part of standard of care.
Study NCT03135184 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HDL Therapeutics PDS-2 System
Description: Delipidation of plasma HDL to reduce coronary atheroma
Study NCT02218060 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary CT angiography on SOMATOM Force
Description: Coronary CT angiography using iodinated contrast; metoprolol and/or nitroglycerin may also be administered on a per-patient basis
Study NCT02218060 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Previous coronary CT angiography on 2nd generation CT scanner
Description: Clinically indicated coronary CT angiography previously performed on a 2nd generation CT scanner
Study NCT03792204 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Wearing-off 9 questionnaire
Description: The participants would receive appropriate anti-PD medical treatments according to the patients' need during the investigation.The anti -PD treatment would not be changed in the population of the participants.
Study NCT01024881 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neutral shoulder position
Description: neutral shoulder position during infraclavicular subclavian catheterization
Study NCT01024881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lowered shoulder position
Description: lowered shoulder position during infraclavicular subclavian catheterization
Study NCT05952895 — intervention group
Intervention type: PROCEDURE
Intervention: Conventional quadrant-wise scaling and root planing (SRP)
Description: SRP was conducted at baseline, after saliva collection and periodontal assessment, starting with the upper right quadrant and continuing clockwise over four visits at weekly intervals. SRP was performed under local anesthesia by the same periodontist (B.A.) by use of ultrasonic instruments (Mini Piezon, EMS, Nyon, CH) and manual periodontal curettes (Gracey curets, scaler Hu-Friedy, Chicago, IL). All present teeth were instrumented until the root surface was visually and tactilely clean and smooth. Self-performed plaque control measures consisted of toothbrushing using the modified Bass technique with a medium toothbrush and a regular toothpaste with fluoride twice a day and interdental cleaning using dental floss and/or interdental brushes once a day.
Study NCT02778828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linezolid
Description: adjustment of Linezolid of based on the AUC/MIC and % T> MIC for each patient to confirm the appropriateness, in light of the peak and residual, and the interest of the split doses more frequently performed in case of too low residual or toxicity.
Study NCT02446327 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling for biomarker assessment
Study NCT02501434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous Low-Dose IV Unfractionated Heparin Infusion
Description: Continuous intravenous infusion of a low-dose unfractionated heparin drip
Study NCT03639558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol + Promethazine + Chlorpromazine
Description: This is the usual treatment given by this hospital during an aggressive psychiatric episode.
Study NCT03063879 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir 400 mg and daclatasvir 60 mg
Description: Daily fixed dose combination pill (Sovodak) containing 400 mg sofosbuvir and 60 mg daclatasvir for 12 weeks if not cirrhotic (liver stiffness \< 12 KPa) or 24 weeks if cirrhotic
Study NCT01914055 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: angio-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)
Description: angio-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan)
Study NCT01914055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OCT-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)
Description: FD-OCT-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan); OCT images will be acquired at the site of culprit coronary artery with a commercially available system (Lunawave System; Fastview catheter/Terumo, Tokio, Japan OR C7 System; LightLab Imaging Inc; C7 Dragonfly catheter/St Jude Medical, Westford, MA)
Study NCT03306953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rectus muscle approximation
Description: The surgeon will take sutures to approximate rectus muscles at the end of cesarean delivery.
Study NCT02791893 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: VNS device
Description: Hand held device to use for self administration of vagus nerve stimulation.
Study NCT02791893 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VNS device
Description: Hand held device to use for self administration of vagus nerve stimulation.
Study NCT02791893 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactive device
Description: Hand held device to use for self administration of simulated vagus nerve stimulation.
Study NCT02109510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nonintubated sedation anesthesia with dexmedetomidine IV, ketamine IV and intercostal nerve block with lidocaine infiltration
Study NCT02109510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas
Study NCT02109510 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: single port thoracoscopic bullectomy
Description: Thoracoscopic bullae resection with automated stapler through the single incision (2.0 cm length) at 5th intercostal space.
Study NCT02109510 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: single port thoracoscopic bullectomy
Description: Thoracoscopic bullae resection with automated stapler through the single incision (2.0 cm length) at 5th intercostal space.
Study NCT01616953 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixmyelocel-T
Description: Twelve days after the bone marrow aspiration, alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with the cell therapy (Ixmyelocel-T)
Study NCT01616953 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autogenous Bone Grafting
Description: Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
Study NCT05055895 — intervention group
Intervention type: DRUG
Intervention: Anticholinergic burden
Description: The anticholinergic burden (ACB) was assessed using the Anticholinergic Burden Scale.~Higher ACB was described as equal or higher than 1.
Study NCT03466359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DEF-EI : Energy restriction induced energy deficit
Description: DEF-EI : Energy restriction induced energy deficit The content of their energy intake will be decreased by 10% daily compared with the phase one of the protocol (stabilization of intake). This decrease will be allowed by the internship nature of the clinical program; all the meals are prepared and served by the personal of the clinical centre.
Study NCT03466359 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: DEF-EX : Exercise induced energy deficit
Description: DEF-EX : Exercise induced energy deficit While their intake will remain the same as phase 1, they will increase their physical activity energy expenditure by 10% thanks to an increase of their prescribed exercise intensities or durations.
Study NCT01833091 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: artificial night
Description: Infants in the intervention group received light cyclic with pattern 12 hours. Light period was from 7 to 19 during which the infants were put in the normal environmental light and dark period was from 19 to 7 during which was the infants' incubator was covered with linen cloth. The vital signsand \& arterial oxygen saturation of the infants in the intervention group were controlled before covering the incubator i.e. at 19. Also, the infant's vital signs were again monitored at 7 am.The infant weighed in every day at 7 am during the 10 days of study. Feeding tolerance was daily determined at 8 am, using nasogastric tube or orogastric tube to control residue as well as to review the presence or absence of abdominal distention, vomiting.
Study NCT04219683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mandibular vertical height augmentation in segmental defects using combined vascularized and non-vascularized fibula flap
Description: Using Free Fibula Flap for reconstruction of mandibular segemental defect
Study NCT03639558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Haloperidol + Promethazine
Description: This is the second most used psycho-pharmacological combination used in this hospital during an aggressive psychiatric episode.
Study NCT01669473 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EHR Based Strategy to promote Safe and Appropriate Drug Use
Description: The printed tools presented in the intervention include:~1. Medication Review: a consolidated list of the medications a patient is currently taking.~2. Medication Sheet: a medication information sheet, including simplified prescription instructions, for each medication that a patient is newly prescribed.~3. Medication List: a table that lists all medications taken by the patient and provides an orientation on how to best organize and simplify their medication regimen
Study NCT01621191 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Administered Orally
Study NCT01046799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir
Description: Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis
Study NCT01286389 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: medical care
Description: Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
Study NCT01286389 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical care
Description: Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)